NOAC reversal: A new landscape of reduced risk

The ‘NOAC reversal: A new landscape of reduced risk’ was a 60-minute interactive symposium discussing NOAC reversal that took place at EUSEM 2018.

Professor John Camm, Professor Sylvia Haas, Dr Deepa Arachchillage and Dr Ander Cohen discussed the emergency management of patients receiving oral anticoagulants, the current anticoagulation reversal options available and how the landscape will be changing in the near future. View the video below to watch the symposium that took place at EUSEM, September 2018, Glasgow.

An enduring e-Learning module is now available on our e-Learning portal. This will allow you to enjoy an experience similar to attending a live symposium, but from anywhere in the world, at completely your own pace.

Register your email and provide your feedback

To help measure the effectiveness of this NOAC Education module, please enter your email below to take part in a short follow-up survey
  • Purpose of the meeting
    The purpose of this meeting was to discuss the emergency management of patients receiving oral anticoagulants, the current anticoagulation reversal options available and how the landscape will be changing in the near future. The intended audience included cardiologists, GPs, nurses, surgeons, anaesthesiologists, emergency physicians and any other healthcare professional with an interest or role in the management of anticoagulation reversal.
  • Learning objectives
    By the end of this activity, participants should be able to:
      • Recognise the factors that affect the choice and dose of oral anticoagulants
      • Describe management options for patients presenting to emergency departments while receiving (or suspected to be receiving) NOACs
      • Recall the different types of anticoagulant reversal agents currently available and the appropriate situations for their use in the UK & Europe
      • Summarise recent developments in NOAC reversal and the relevant clinical applications
     
  • Speakers
  • Funding
    This independent educational activity is supported by funding from Portola Pharmaceuticals. PCM Scientific is the medical education company acting as scientific secretariat and satellite symposium organiser for this programme.